1. Home
  2. CLVT vs IVA Comparison

CLVT vs IVA Comparison

Compare CLVT & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clarivate Plc

CLVT

Clarivate Plc

HOLD

Current Price

$2.14

Market Cap

1.3B

Sector

Technology

ML Signal

HOLD

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$4.65

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLVT
IVA
Founded
2016
2011
Country
United Kingdom
France
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
CLVT
IVA
Price
$2.14
$4.65
Analyst Decision
Hold
Strong Buy
Analyst Count
7
10
Target Price
$3.22
$16.20
AVG Volume (30 Days)
5.1M
673.2K
Earning Date
04-29-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
68.75
N/A
EPS
N/A
N/A
Revenue
$974,345,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.12
$751.20
P/E Ratio
N/A
N/A
Revenue Growth
0.61
N/A
52 Week Low
$1.66
$3.35
52 Week High
$4.54
$7.98

Technical Indicators

Market Signals
Indicator
CLVT
IVA
Relative Strength Index (RSI) 56.44 52.98
Support Level $2.09 $4.48
Resistance Level $2.69 $4.70
Average True Range (ATR) 0.12 0.16
MACD 0.04 -0.02
Stochastic Oscillator 97.22 39.80

Price Performance

Historical Comparison
CLVT
IVA

About CLVT Clarivate Plc

Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

Share on Social Networks: